Overview

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor site after the tumor is surgically removed (resection). In addition, the patient will receive radiation therapy and may or may not be treated with oral temozolomide.

Phase:

Phase 1

Details

Lead Sponsor:

INSYS Therapeutics Inc

Treatments:

Dacarbazine
Temozolomide